Evidence map›Paper›PMID 31024841›Full record

ArticleFrontiers in oncology2019

Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer.

Yangjiong Xiao, Yang Yu, Dan Gao, Wangrui Jin, Pengcheng Jiang, Yuhong Li, Chao Wang, Yuning Song, Peng Zhan, Fei Gu and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Yangjiong XiaoDepartment of Obstetrics and Gynecology, Shanghai Fengxian District Central Hospital of Southern Medical University, Shanghai, China.
Yang YuShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Dan GaoShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Wangrui JinShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Pengcheng JiangDepartment of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, China.
Yuhong LiDepartment of Gynecology, The International Peace Maternity & Child Health Hospital, The China Welfare Institute, Shanghai Jiaotong University, Shanghai, China.
Chao WangDepartment of Gynecology, The International Peace Maternity & Child Health Hospital, The China Welfare Institute, Shanghai Jiaotong University, Shanghai, China.
Yuning SongDepartment of Clinical Pharmacy, Qilu Hospital of Shandong University, Jinan, China.
Peng ZhanDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, China.
Fei GuDepartment of Obstetrics and Gynecology, Shanghai Fengxian District Central Hospital of Southern Medical University, Shanghai, China.
Cancan ZhangDepartment of Obstetrics and Gynecology, Shanghai Fengxian District Central Hospital of Southern Medical University, Shanghai, China.
Bin WangDepartment of Obstetrics and Gynecology, Shanghai Fengxian District Central Hospital of Southern Medical University, Shanghai, China.
Yihua ChenDepartment of Obstetrics and Gynecology, Shanghai Fengxian District Central Hospital of Southern Medical University, Shanghai, China.
Bing DuDepartment of Obstetrics and Gynecology, Shanghai Fengxian District Central Hospital of Southern Medical University, Shanghai, China.
Rong ZhangDepartment of Obstetrics and Gynecology, Shanghai Fengxian District Central Hospital of Southern Medical University, Shanghai, China.
East China Normal University · CNSouthern Medical University · CNInternational Peace Maternity & Child Health Hospital · CNXian Central Hospital · CNNanjing Medical University · CNQilu Hospital of Shandong University · CNShandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel inhibitors are urgently needed for use as targeted therapies to improve the overall survival (OS) of patients with ovarian cancer. Here, we show that cell division cycle 25B (CDC25B) is over-expressed in ovarian tumors and associated with poor patient prognosis. All previously reported CDC25B inhibitors have been identified by their ability to reversibly inhibit the catalytic dephosphorylation activity of CDC25B

Indexed as

ovarian cancerPDXprimary cell linestarget therapyWG-391D

Identifiers

PMID31024841
PMCPMC6463794
OpenAlexW2939285995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.